BHB Reduced Anxiety by 40% in Women — What the Clinical Data Actually Shows
By: Bonnie Barber
A clinical study on the combination of BHB salts and MCT is producing results the supplement industry rarely sees — measured by instruments the pharmaceutical industry uses to evaluate prescription anxiety drugs. And buried in the fine print is the most important detail: 84% of the subjects were women. For a category that has been historically under-researched, this is a signal worth paying attention to.
The Women’s Brain Health Data We’ve All Been Missing
Of the 57 subjects in this 8-week clinical study, 48 were women. That detail has been treated as a demographic footnote in most conversations about the research. It shouldn’t be.
Women’s brain health is one of the most under-served, fastest-growing, and least clinically-supported conversations in wellness today. Perimenopause cognition. Hormonal anxiety. Midlife brain fog in the 35-to-55 window. Female-specific cognitive decline, including the fact that Alzheimer’s disease disproportionately impacts women.
Pharmaceutical options are limited. Supplement options are largely unvalidated. And the research community has historically skewed male in its study populations.
This study is different — and the results are hard to dismiss.
The Headline Results
Over 8 weeks, subjects received a formula of 8 grams of BHB salts and 2 grams of C8 MCT, the results showed:
- 40% reduction in mild anxiety (measured by HAM-A)
- ~39 millisecond improvement in reaction time (measured by WAVi P300)
- Results achieved without ketosis — subjects were not on a ketogenic diet
Another formula of 2 grams of BHB salts and 8 grams of C8 MCT in the same study showed a 24% anxiety reduction, confirming that BHB drives outcomes.
Why the Measurement Tools Matter More Than the Numbers
Any supplement company can publish a study. What separates credible clinical research from marketing noise is the instruments used to measure it. This study used three of the most respected assessment tools in modern clinical science.
HAM-A (Hamilton Anxiety Rating Scale)
The HAM-A has been the gold-standard clinical instrument for measuring anxiety severity since 1959. It’s the scale psychiatrists use in FDA pharmaceutical trials to evaluate anti-anxiety medications. When a drug company wants to prove their anxiety medication works, HAM-A is the ruler they have to move.
A 40% HAM-A reduction is being measured on the same clinical scale as prescription pharmaceuticals.
WAVi P300
The WAVi P300 is an FDA-cleared EEG-based device that measures evoked brain response — the actual electrical signal a neuron fires in response to a stimulus. The P300 marker is one of the most-studied signals in cognitive neuroscience, used in concussion research, cognitive aging studies, and neurological assessment.
This is not self-reported reaction time. It’s not a wearable. It is measurable brain activity. And in this study, neural processing was nearly 40 milliseconds faster in the stronger BHB group.
Trail Making Tests (A and B) and the Flanker Test
These are standard neuropsychological assessments used in clinical dementia screening, traumatic brain injury evaluation, and executive function research at hospitals and research institutions worldwide. Trail Making measures cognitive flexibility and processing speed. The Flanker test measures attention control and the brain’s ability to suppress irrelevant information.
Stack these three instruments together, and the measurement framework on this study is stronger than what most supplement studies ever come close to.
Why This Matters for Women’s Brain Health Specifically
The intersection of three factors makes this data uniquely significant:
A female-weighted cohort. The benefits showed up in a population that is typically under-represented in clinical research.
Pharmaceutical-grade instrumentation. The results are measured by the same tools used to evaluate prescription drugs and neurological conditions.
No ketosis required. The anxiety and cognitive benefits occurred at standard dosing in a non-ketogenic population — meaning BHB’s neurological effects are accessible to women who want support without adopting a keto lifestyle.
For a category searching for clean, credible, clinically-supported options, this is rare evidence.
What This Means for Formulators and Brand Partners
Three strategic takeaways for brands building with BHB:
Formulation ratio drives clinical outcomes. The two groups in this study received different BHB-to-MCT ratios and produced meaningfully different results. Not all BHB products deliver equivalent benefits — and that is a real differentiation story for partners formulating with precision.
Category expansion is clinically supported. BHB’s neurological and emotional benefits appear in non-ketotic subjects. This opens validated category plays in women’s health, stress support, cognitive performance, and midlife wellness — not just keto-specific SKUs.
Claims substantiation is stronger than typical. HAM-A, WAVi P300, and the Trail Making assessments carry weight in regulatory and scientific conversations. Brands building with goBHB can point to clinical-grade data using instruments that are difficult to hand-wave away.
Study Details and Honest Context
Design: Single-blind comparison of two BHB-MCT formulations over 8 weeks, twice-daily dosing, one being 8 grams of BHB salts and 2 grams of C8 MCT, the other 2 grams of BHB salts and 8 grams of C8 MCT.
Subjects: 57 adults (48 women, 9 men), ages 20–70, BMI 20–40, no diabetes or hyperlipidemia
Key comparison group: 33 subjects
Instruments: HAM-A, WAVi P300 (FDA-cleared), Mini-Mental State Exam, Trail Making A/B, Flanker test, full blood panel, body composition tracking
This is directional clinical data with strong methodology, not a pharmaceutical monograph. Sample size is modest, and the study is industry-funded — disclosures that belong in any honest conversation about supplement research. But the instruments, the effect size, and the demographic skew make it one of the more compelling data points in the BHB category today.
The Bottom Line
The supplement industry has been running on trends. Pharma has been writing prescriptions. Women in the 35-to-55 window have been left with almost nothing clean, credible, or clinically supported for anxiety and cognitive clarity.
This study changes the conversation. BHB in the right formulation ratio, produced pharmaceutical-grade results on pharmaceutical-grade instruments, in a predominantly female cohort.
That’s not a side note. That’s a category opening.
Frequently Asked Questions
Can BHB help with anxiety in women?
A recent 8-week clinical study showed that a BHB-MCT formulation reduced mild anxiety scores by 40% in a predominantly female cohort (48 of 57 subjects were women), as measured by the Hamilton Anxiety Rating Scale — the same instrument used in FDA pharmaceutical trials.
Do you have to be in ketosis for BHB to work?
No. In this study, subjects were not in ketosis. The anxiety reduction and cognitive improvements occurred at standard dosing in a non-ketogenic population, meaning BHB’s neurological benefits are accessible without a keto diet.
What is the HAM-A and why does it matter?
The Hamilton Anxiety Rating Scale (HAM-A) is the gold-standard clinical instrument for measuring anxiety severity. It has been used since 1959 and is a primary tool in FDA pharmaceutical trials for anti-anxiety medications. A 40% HAM-A reduction is a clinically significant result.
How does BHB affect brain function?
BHB crosses the blood-brain barrier and is used directly as neural fuel. It produces more ATP per unit of oxygen than glucose and generates fewer reactive oxygen species, meaning cleaner cellular energy for neurons. In this study, reaction time improved by nearly 40 milliseconds as measured by the WAVi P300 EEG device.
Is this study strong enough to act on?
The study used clinical-grade instruments (HAM-A, WAVi P300, Trail Making, Flanker), had a controlled 8-week design, and produced statistically meaningful results. It’s industry-funded with a modest sample size — so treat it as strong directional support, not a pharmaceutical monograph. The instruments and effect sizes make it one of the more credible data points in the BHB category.